Somatostatin receptor imaging (SRI) with [111 In-DTPA 0] octreotide has proven its role in
the diagnosis and staging of gastroenteropancreatic neuroendocrine tumors (GEPNETs) …

Oncogenic osteomalacia (OO) is a rare paraneoplastic syndrome of osteomalacia due to
phosphate wasting. The phosphaturic mesenchymal tumor (mixed connective tissue …

Tumor‐induced osteomalacia (TIO) is an acquired form of hypophosphatemia. Tumor
resection leads to cure. We investigated the clinical characteristics of TIO, diagnostic …

This Brief Report describes a patient with the rare syndrome of tumor-induced osteomalacia,
which is accompanied by phosphaturia and hypophosphatemia. Renal phosphate wasting …

Tumor-induced osteomalacia (TIO) is a paraneoplastic disorder characterized by
hypophosphatemia, phosphaturia, inappropriately low serum levels of 1, 25 …

Objectives Tumor-induced osteomalacia (TIO) is generally caused by small benign
mesenchymal tumors producing fibroblast growth factor-23 (FGF-23). The only curative …

Abstract Tumor-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a
rare paraneoplastic syndrome characterized by hypophosphatemia resulting from …

Oncogenic osteomalacia has fascinated physiology-minded physicians for decades. The
traditional name for this peculiar disorder connotes its classification as a paraneoplastic …

Tumor-induced osteomalacia (TIO) is a paraneoplastic syndrome characterized by renal
phosphate wasting, hypophosphatemia and low calcitriol levels as well as clinical symptoms …

Background Tumor-induced osteomalacia is a paraneoplastic syndrome resulting in renal
phosphate wasting and decreased bone mineralization. Phosphaturic mesenchymal tumors …